Description
This week on "The Top Line," Fierce Biotech staff writer Gabrielle Masson and senior editor Annalee Armstrong look back at the year in biotech, which was defined by massive layoffs across the industry. They also discuss their favorite stories of the year, including an appearance from a popstar whose reputation precedes her.
To learn more about the topics in this episode:
Biotechs end year 'trading for nothing' as investors mull 'what is IPO-able today?'
Fierce Biotech Layoff Tracker 2023
Editor's Corner—When ASCO dueled with the world's biggest pop star, Swift Biotech was ready for it
Alzheimer's meds are here. But for the Down syndrome community, it's still the 1980s
See omnystudio.com/listener for privacy information.
The Fierce Biotech team published a four-part series this week exploring cell therapy, a modality that has faced clinical challenges, manufacturing constraints and multiple practice-changing events.
In today’s episode, Fierce’s Annalee Armstrong and Gabrielle Masson discuss the series of...
Published 05/31/24
This week’s episode of “The Top Line,” is the final part of a three-part series diving into the latest advancements in cell and gene therapy manufacturing.
In this episode, Fierce Pharma’s Fraiser Kansteiner is joined by Bruce Levine, Ph.D., who is the co-inventor of Kymriah and the Barbara and...
Published 05/24/24